{"links":{"html":"https://www.erudio.com/reports/krascendo-3-nct07541170","json":"https://www.erudio.com/reports/krascendo-3-nct07541170.json","markdown":"https://www.erudio.com/reports/krascendo-3-nct07541170.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"krascendo-3-07541170"}},"request":"https://www.erudio.com/contact?report=krascendo-3-07541170"},"offer":{"cited_commentary_sources":6,"verified_hcp_statements":10,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":4,"optional":true,"price_per_verified_person_usd":15,"price_usd":60,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"krascendo-3-nct07541170"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=krascendo-3-07541170","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/krascendo-3-nct07541170","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T15:06:50.045025Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":5,"no_commentary_found":6},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Disease-free Survival (DFS), as Determined by the Investigator"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":0,"title":"Secondary endpoint: Overall Survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":0,"title":"Secondary endpoint: DFS Rates at 2 and 3 Years, as Assessed by the Investigator"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":0,"title":"Secondary endpoint: Number of Participants With Adverse Events (AEs)"},{"claim_count":1,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":0,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T8","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":1,"title":"NAUTIKA1 and the threshold for standard care"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":3,"title":"NAUTIKA1 feasibility as a rationale for postoperative evaluation"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Early-stage interest and the durable-benefit question"}],"counts":{"cited_sources":7,"claims_by_expression_type":{"interpretation":3,"opinion":2,"primary_context":2,"question":1,"restatement":2},"claims_by_kind":{"protocol_statement":2,"source_observation":8},"clinician_statements":4,"evidence_units":9,"findings":3,"organisational_accounts":2,"people_cited":4,"people_identity_verified":4,"people_total":4,"screened_sources":14,"verified_claims":10},"findings_index":[{"id":"F1","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"A favorable nodal observation does not amount to standard-care endorsement"},{"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":4},"has_counterview":true,"limitations":4,"links":{"context":1,"support":7},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"registry":1}},"title":"NAUTIKA1 is read as a feasibility rationale for further evaluation"},{"id":"F3","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Early-stage interest leaves durable patient benefit as an open question"}],"medical_affairs_question":"What postoperative evidence would justify moving from a feasibility signal to routine-care adoption?","sections":{"analysis":[{"id":"section-1","level":3,"title":"A nodal signal is not an endorsement of standard care"},{"id":"section-2","level":3,"title":"NAUTIKA1 supplies a feasibility rationale, with explicit evidentiary limits"},{"id":"section-3","level":3,"title":"Early-stage interest leaves the durable-benefit question unanswered"},{"id":"section-4","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Disease-free Survival (DFS), as Determined by the Investigator"},{"findings":[],"id":"T2","label":"Secondary endpoint: Overall Survival (OS)"},{"findings":[],"id":"T3","label":"Secondary endpoint: DFS Rates at 2 and 3 Years, as Assessed by the Investigator"},{"findings":[],"id":"T4","label":"Secondary endpoint: Number of Participants With Adverse Events (AEs)"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[],"id":"T6","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":2}],"id":"T7","label":"Safety and tolerability"},{"findings":[],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T15:06:50.045025Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T15:15:49Z","record_hash":"3a95a18cbbd777de086f2007a944c5f28f8e2421f5db2c73e0df0670d5bb1367","release_hash":"dc39c00b5a8657974c595b66e62c4b8ddf958677a13946fb83cecc9a2c6d6410","report_id":"erudio-nct07541170","run_id":"e996b4a7-112e-4802-85d2-d58407c2d5d3","schema_version":"5.0","slug":"krascendo-3-07541170","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"KRASCENDO 3 tests whether divarasib improves disease-free survival after resection of stage II–III KRAS G12C-positive non-small cell lung cancer; discussion centers on a favorable NAUTIKA1 nodal observation and the threshold for standard-care endorsement. The report cites three medical oncologists. Further questions concern NAUTIKA1’s role in additional evaluation and durable patient benefit from early-stage KRAS G12C inhibition. What postoperative evidence would justify moving from a feasibility signal to routine care?","meta_description":"14 sources screened · 10 verified statements (4 from clinicians verified by NPI or staff page) from 7 sources · 3 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-0d3399c31d2aab6d5e2e"],"id":"F2","paraphrase":"An organizational X thread prompts a methodological question about how neoadjuvant NAUTIKA1 evidence should inform postoperative evaluation in KRASCENDO 3.","publication_caveats":["The thread summarizes publicly released abstract material, not presentation slides."],"source_channel":"x_thread","source_date":"2026-09-03","title":"NAUTIKA1 is read as a feasibility rationale for further evaluation"},{"cited_claim_ids":["claim-3a16478d08ca9c54266d"],"id":"F3","paraphrase":"A medical oncologist’s LinkedIn post provides context for asking how to assess the scope of durable-benefit commentary.","publication_caveats":{"reason":"Publication caveats for this post are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"linkedin_post","source_date":"2026-10-19","title":"Early-stage interest leaves durable patient benefit as an open question"}]},"publication":{"approved_at":"2026-11-01T15:15:49Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":14},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The views come from the sources reviewed for this edition, not a representative sample of HCP opinion. Multiple posts discuss the same NAUTIKA1 cohort and should not be counted as independent clinical evidence.","Coverage concentrated on the trial identifier and known names. Unnamed references and different transcriptions may be missing, and several potentially relevant passages have not been fully assessed.","No publication reporting NCT07541170 was identified, no separate protocol document was listed in the registry, and no exact divarasib regulatory label was found. These absences do not establish publication or regulatory status.","The substantive activity, surgical-feasibility and tolerability observations concern a small neoadjuvant phase II NAUTIKA1 cohort, not randomized postoperative KRASCENDO3 outcomes.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A speaker's statement relays another party's early-stage perspective; it should not be treated as his own regimen-specific recommendation."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":5,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":6,"methods":1},"count":7,"evidence_window":{"end":"2026-10-19","start":"2026-05-10"},"retrieval_snapshot":"2026-11-01T14:49:21.221196Z","timeline":[{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W36"},{"count":3,"week":"2026-W37"},{"count":1,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT07541170:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07541170:context","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:f570b9c4-6846-4de2-abfa-4d0a4ae4e394:20260812","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4axwsf5hlk2omckvoolonim6-3myqlodzi7w42","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7518009110118903808","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053391169204232207:245d86aa-e116-4d42-8e78-88786006c7df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060762834737520746:08a20bb2-582f-4498-990e-772c1ac22df1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072592258688245969:1317675c-b33b-4d4f-a0c0-2d5af8e73df3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075639468753907910:93d87de6-e467-439d-909f-e0028bd13e45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095482328692761056:a12e1178-c44b-4742-8218-89d6583ff5fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098179711897633053:b2320978-a438-487f-80d3-ed8e00b633be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099028897144926437:c8cbcb1d-e78d-4021-96ed-5e92f8bf24fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099032435459866940:a26b8ebf-f11f-463e-8782-e5687364f665","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108910705327943937:573d783b-642b-4075-9fef-22edad3b89e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108937855795925109:4c63bfd0-fa5f-4c82-841d-a1e7e7556204","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114381744980062426:1053594e-5658-4688-8f97-80629bf4cb1f","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:EiBsJ_w6q0E","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":11,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":14},"count":14,"evidence_window":{"end":"2026-10-31","start":"2026-05-10"},"retrieval_snapshot":"2026-11-01T14:49:21.558594Z","timeline":[{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W36"},{"count":3,"week":"2026-W37"},{"count":2,"week":"2026-W41"},{"count":2,"week":"2026-W43"},{"count":2,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"divarasib","slug":"divarasib"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"KRASCENDO 3","aliases":["KRASCENDO 3","A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)","A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer"],"brief_title":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-small Cell Lung Cancer"],"display_condition":"resected stage II-III KRAS G12C-positive NSCLC","display_interventions":[["divarasib"]],"enrollment":{"count":400,"type":"ESTIMATED"},"interventions":[{"name":"Divarasib","synonyms":["RO743584; GDC-6036"],"type":"DRUG"},{"name":"Pembrolizumab","synonyms":["Keytruda"],"type":"DRUG"},{"name":"Nivolumab","synonyms":["Opdivo"],"type":"DRUG"}],"nct_id":"NCT07541170","official_title":"A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2032-01-31","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Disease-free Survival (DFS), as Determined by the Investigator","timeFrame":"From randomization to disease recurrence or death from any cause (Up to approximately 5 years)"}],"registered_date":{"date":"2026-04-21","type":"ACTUAL"},"registry_last_updated":"2026-10-13","registry_url":"https://clinicaltrials.gov/study/NCT07541170","short_name":"KRASCENDO 3","short_name_basis":"registry_acronym","sponsor":"Hoffmann-La Roche","start_date":{"date":"2026-10-06","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"BO45885","type":"sponsor_study_id"},{"id":"2025-524263-21-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}